The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
Information source: University of Oklahoma
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Catheterization
Intervention: Clopidogrel (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Oklahoma Official(s) and/or principal investigator(s):
Eliot Schechter, MD, Principal Investigator, Affiliation: University of Oklahoma
Overall contact:
Eliot Schechter, MD, Phone: 405-270-0501, Ext: 5378, Email: eliot-schechter@ouhsc.edu
Summary
This study will explore the effect of clopidogrel on coated-platelets in patients who are
given an loading dose before diagnostic catheterization or percutaneous coronary
intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that
are coated and therefore more hypercoagulable.
Clinical Details
Official title: The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
Study design: Basic Science, Open Label, Single Group Assignment
Primary outcome: Change in the percentage of coated platelets
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients given clopidogrel loading dose before scheduled catheterization or
percutaneous intervention
Exclusion Criteria:
- Acute coronary syndrome
- Unable to tolerate clopidogrel
Locations and Contacts
Eliot Schechter, MD, Phone: 405-270-0501, Ext: 5378, Email: eliot-schechter@ouhsc.edu
VA Medical Center, 1F187, Oklahoma City, Oklahoma 73104-5076, United States; Recruiting
Eliot Schechter, MD, Principal Investigator
Additional Information
Starting date: March 2007
Ending date: June 2008
Last updated: March 27, 2008
|
